Last reviewed · How we verify
Fentanyl infusion
Fentanyl infusion, marketed by Ain Shams University, is a well-established analgesic in the healthcare sector. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. However, the lack of reported revenue and primary trial results poses a risk in assessing its commercial and clinical performance.
At a glance
| Generic name | Fentanyl infusion |
|---|---|
| Also known as | Opioid |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Total Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy (PHASE4)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Parascapular Sub Iliocostalis Plane Block Versus Thoracic Paravertebral Plane Block for Traumatic Multiple Rib Fractures (NA)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Comparison of Fentanyl and Magnesium to Control Reflex Hemodynamics in Patients Aged 50 and Older (NA)
- Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery (NA)
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |